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Background: In our previous study, a novel liver-targeting fusion interferon (IFN-CSP) combining IFN α2b with
plasmodium region I peptide was successfully constructed. IFN-CSP has significant inhibition effects on HBV-DNA
replication in HepG2.2.15 cells. The aim of the present investigation was focused on how to produce high levels
of recombinant IFN-CSP and its in vivo anti-hepatitis B virus (HBV) activity.
Methods: A modified DNA fragment encoding IFN-CSP was synthesized according to Escherichia coli (E. coli)
preferred codon usage and transformed into E. coli BL21 (DE3) for protein expression. The induction conditions
were systematically examined by combining one-factor experiments with an orthogonal test (L(9)(3)(4)). The
antigenicity of the purified protein was characterized by western blot analysis. The in vivo tissue distribution were
assayed and compared with native IFN α2b. HBV-transgenic mice were used as in vivo model to evaluate the
anti-HBV effect of the recombinant IFN-CSP.
Results: The results showed that the E. coli expression system was very efficient to produce target protein.
Conclusion: Our current research demonstrates for the first time that IFN-CSP gene can be expressed at high
levels in E. coli through codon and expression conditions optimization. The purified recombinant IFN-CSP showed
liver-targeting potentiality and anti-HBV activity in vivo. The present study further supported the application of
IFN-CSP in liver-targeting anti-HBV medicines.
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HBV transgenic miceBackground
Over the past decade, a number of functional proteins
have been produced successfully by recombinant DNA
methods [1, 2]. The most commonly used host cell is
Escherichia coli (E. coli) because of high yield and low
cost [3]. However, high-level expression of recombinant
proteins using E. coli as the host cell has been affected* Correspondence: luxuemei605@163.com; zhujiayong1020@163.com
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creativecommons.org/publicdomain/zero/1.0/by some factors, such as the different preferential codons
in different expression systems and various induction
conditions of target protein [4, 5].
The interferons (IFNs) are a family of protein with the
ability to induce antiproliferative, immunomodulatory,
and antiviral activities [6–8]. For more than a decade,
interferon therapy is the gold standard in treatment for
certain forms of viral hepatitis and carcinogenesis [9].
However, therapeutic efficacy has been limited because
interferon does not have organ-specific affinity and its
in vivo half-life is short [10]. Incorporation of plasmodium
region I peptide was demonstrated to be a promising
strategy for the development of liver-targeting drug
[11, 12]. In our previous study, a novel liver-targetingdistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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plasmodium region I peptide was successfully designed
[13]. The results of in vitro anti-hepatitis B virus (HBV)
activity of IFN-CSP showed that IFN-CSP has significant
inhibition effects on HBV-DNA replication in HepG2.2.15
cells [14]. In vitro liver tissue binding analysis revealed that
IFN-CSP specific targeting to liver tissue [13]. IFN-CSP
may be an excellent candidate as a liver-targeting anti-
HBV agent. However, the in vivo tissue distribution and
anti-HBV activity of IFN-CSP requires further investigate.
Moreover, it is desirable to produce IFN-CSP in a large
scale for therapeutic application.
The main purpose of the present investigation was
focused on how to produce high levels of recombinant
IFN-CSP in a cost-effective way. We also investigated
the in vivo tissue distribution and anti-HBV activity of
IFN-CSP. Therefore, a modified DNA fragment encod-
ing the IFN-CSP was synthesized by overlapping
extension-PCR method according to E. coli preferred
codon usage. The IFN-CSP gene was cloned into the
bacterial expression vector pET-21b and transferred
into the expression strain E. coli BL21. The suitable in-
duction conditions were systematically optimized by
combining one-factor experiments with an orthogonal
experiment (L(9)(3)(4)). The antigenicity of the puri-
fied protein was characterized by western blot analysis.
The in vivo tissue distribution were assayed and com-
pared with native IFN α2b. HBV-transgenic mice were
used as in vivo model to evaluate the anti-HBV effect


















*Letters in italic denote the overlapped parts in IFN-CSP. Restriction sites are underlMethods
Pasmids, strains and culture media
pMD20-T (Takara, Japan) was used for gene cloning.
pET-21b (Novagen, USA) was employed to construct ex-
pression vector. E. coli strain DH5α (Novagen, USA) was
applied as the host for gene manipulation. E. coli strain
BL21 (DE3; Novagen, USA) served as expression host
for fusion protein. Luria-Bertani (LB) medium was used
for bacterial growth and protein expression.
Construction of the liver-targeting fusion interferon gene
using E. coli preferred codon
To improve the expression level of IFN-CSP in E. coli, a
new IFN-CSP coding sequence was designed. The opti-
mized codons usage pattern of E. coli genes was employed
according to the codon usage pattern of E. coli (http://
www.kazusa.or.jp/codon/). Based on the method of poly-
merase chain reaction (PCR)-based gene synthesis and
gene splicing by overlap extension, a modified three-step
method [15], called “splicing by overlapping extension-
PCR (SOE-PCR)”, was adopted to construct the synthetic
IFN-CSP gene. We designed 16 oligonucleotides encoding
for the IFN-CSP protein. The sense and antisense oligonu-
cleotides with 19 bp complementary overlapping sequence
are presented in Table 1.
Construction of expression plasmids IFN-CSP/pET-21b
The synthetic IFN-CSP gene fragments were cloned into the
pMD20-T vector (Takara) and transformed into E. coli DH5a
according to the procedures described by the manufacturer.embly of IFN-CSP*

















ined. Bold type indicates the additional terminal codon ‘TAAT’
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were digested and the inserts were cloned into Nde I/Xho I re-
striction sites of the expression vector pET-21b (Fig. 1a). The
resulting expression plasmid IFN-CSP/pET-21b was finally
transformed into E. coli BL21 (DE3) for IFN-CSP expression.
Optimization of IFN-CSP expression
To improve the expression level of IFN-CSP, the induc-
tion conditions [16] like cultivation temperature, induc-
tion timing, inducer concentrations, induction time were
systematically examined by combining one-factor experi-
ments with an orthogonal test (L(9)(3)(4)). A fresh clone
of recombinant E. coli BL21 with plasmid IFN-CSP/
pET-21b grew in Luria-Bertani (LB) medium containing
100 μg/ml ampicillin. Different conditions of induction
(temperatures: 17 °C, 22 °C, 27 °C, 32 °C, 37 °C, 42 °C;
OD600: 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 2.0; IPTG concentra-
tions: 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.5 mM; induction
times: 1, 2, 4, 6, 8, 10, 12, 24 h) were conducted to
optimize the expression of heterologous protein in E.
coli. To evaluate the expression level of IFN-CSP, the
cells were harvested by centrifugation at 10,000 rpm for
10 min. Samples were analyzed by 15 % sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and the percentage fraction of proteins was assessed by
densitometric using Gel-Pro analyzer Version 4.5 soft-
ware. Total protein concentration was determined by
Bradford method and the concentration of IFN-CSP was
calculated according the percentage fraction and total
protein concentration.
Purification, antigenicity and biological activity analysis
Cells were collected by centrifugation. After lysis by
ultrasonication in an ice bath, an improved seven-stepFig. 1 Schematic diagram of IFN-CSP gene in the expression vector IFN-CSP/pE
A Schematic diagram of IFN-CSP/pET-21b (T7 pro, T7 promoter; T7 ter, T7 termin
weight marker, Lane 1–2: Total proteins of E. coli BL21/pET-21b-IFN-CSP b
after ultrasonication and centrifugationprocess was conducted to obtain purified IFN-CSP based
on previously described methods [13, 15, 17]. Briefly,
cellular pellet was separated from the cell lysate by cen-
trifugation at 6000 g and 4 °C for 10 min. IB material
was washed with 1 % Triton X-100 and 2 M urea (con-
taining 2 % deoxycholate), and then dissolved in 6 M
guanidine hydrochloride (GuHCl) (containing 2.5 mM
DTT and 50 mM Tris-HCL buffer, pH 8.0). The solubi-
lized IFN-CSP was refolded by dialysis with the 50 mM
Tris-HCl buffer systems (containing 0.2 mM glutathione
oxidized and 2 mM glutathione reduced), followed by
changes of the buffer containing decreasing GuHCl con-
centrations (4, 2 and 1 M) and finally with Tris-HCl buf-
fer (pH 7.4). The refolded IFN-CSP was purified by
heparin affinity chromatography according to the in-
struction of HiTrap affinity column (GE healthcare,
USA). The IFN-CSP was eluted with a linear gradient of
0.1–2 M NaCl. After dialysis against the Tris-HCl buffer,
the sample was further purified to remove endotoxin by
polymyxin B column (Bio-Rad, USA). After detecting
the lipopolysaccharides (LPS) content with the chromo-
genic limulus amoebocyte lysate assay (Associates of
Cape Cod, USA), the purified IFN-CSP was lyophilized
and stored at -80 °C.
The antigenicity of the purified protein was character-
ized by western blot analysis. We performed western
blot with primary goat polyclonal anti-IFN α antibody
(1:200; Santa Cruz Biotechnology, USA) and peroxidase-
conjugated rabbit anti-goat IgG (1:2500; Santa Cruz Bio-
technology, USA) as previously described [13]. The pur-
ity of the purified protein was assessed by reverse phase
high-performance liquid chromatography (RP-HPLC) on
a C18 column (250 × 4.6 mm, 5 μm, and 300 Å, Agilent,
USA) in an analytical Alliance HPLC System (Waters,T-21b and expression of IFN-CSP protein in E. coli BL21/pET-21b-IFN-CSP. a:
ator). b: SDS-PAGE analysis of protein expression. Lane M: Protein molecular
efore and after induction, Lane 3–4: Supernatant and precipitation
Fig. 2 The IFN-CSP gene with codon optimization. The codons in frame are optimized
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characterized by mass spectrometry on a matrix-assisted
laser desorption/ionization (MALDI) mass spectrometer
(Applied Biosystems, USA).
Biological activity of IFN-CSP was determined in a
standard cytopathic effect inhibition assay using vesicular
stomatitis virus (VSV)/human amniotic cells (WISH) meas-
ure system according to China Biologicals Requirements.Fig. 3 Construction of fusion gene IFN-CSP. Lane M: DNA molecular weigh
Lane 9–12: The second PCR products ranging 132–175 bp in size, Lane 13:In vivo tissue distribution experiment
All animal experimental protocols were approved by the
Guangdong Pharmaceutical University Animal Care and
Use Committee. Normal Balb/c mice (18–22 g) were
purchased from the Center for Experimental Animals of
Guangdong Province (Guangzhou, China). Balb/c mice
(n = 90) were injected via the tail vein with 9.01 μg/kg
(0.46 nmol/kg) of control IFN α2b or 10.09 μg/kg (0.46t marker, Lane 1–8: The first PCR products ranging 68–97 bp in size,
Target amplification the full-length fusion gene IFN-CSP
Fig. 4 Effect of temperature on the expression level of IFN-CSP in E. coli BL21/pET21b-IFN-CSP. a: SDS-PAGE analyses of IFN-CSP expression under
different temperatures. Lane M: Protein molecular weight marker; Lane 1: E. coli BL21/pET21b-IFN-CSP before induction; Lanes 2–7: E. coli BL21/
pET21b-IFN-CSP was cultured at 17, 22, 27, 32, 37 and 42 °C, respectively. b: Percentage and concentration of IFN-CSP were calculated by the target
bands in SDS-PAGE (A)
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and 480 min post injection, the mice were anesthetized,
euthanized and then the liver, heart, spleen, lung and
kidney were excised, rinsed with saline, dried and weighed.
The concentration of IFN α2b was determined by ELISA
(Shanghai Senxiong Biotechnology Limited Corporation.)
according to the manufacturer.
In vivo anti-HBV experiment
Balb/c-HBV transgenic mice (18–22 g) were purchased
from Infectious Disease Center of No. 458 Hospital
(Guangzhou, China) and kept under the pathogen free
condition in the facility of the Guangdong Pharmaceutical
University. The Balb/c-HBV transgenic mice were randomly
assigned to either treatment or control groups (n = 6). Six
non-transgenic Balb/c mice were used as normal control
mice. Each mouse was intramuscular injected with IFN-CSP
(at dose of 101 U/g body weight, 102 U/g body weight, 103
U/g body weight, respectively) once a day for 28 days. Sterile
physiological saline was used as control. IFN α2b (103 U/g
body weight) was used as drug control. Mice were sacrificed
at day 28. Serum samples and livers were collected.Fig. 5 Effect of cell density on the expression level of IFN-CSP in E. coli BL21/
growth stages. Lane M: Protein molecular weight marker; Lane 1: E. coli BL21/
was induced at OD600 value of 0.1, 0.2, 0.4, 0.6, 0.8, 1.0 and 2.0, respectively. b:
bands in SDS-PAGE (A)Measurement of serum HBsAg and HBV-DNA
Serum HBsAg was measured by enzyme-linked immuno-
sorbent assay (ELISA) using a HBV diagnostic kit (Shanghai
Kehua Biotech Co. Ltd., China) following the manufacturer’s
recommendations. Serum HBV-DNA was measured using a
commercially available real-time fluorescent quantification
PCR (FQ-PCR) diagnostic kit (Da-An Gene Co., Guangzhou,
China) according to the manufacturer’s instruction.
Immunofluorescence and western blot analysis for HBV
core protein
Tissues were fixed in 4 % paraformaldehyde for 1 h, then
in 30 % sucrose solution overnight for cryoprotection.
10–12 μm thick sections were cut using a Leica cryostat.
Immunohistological detection of HBcAg was performed
on frozen sections using primary rabbit polyclonal anti-
HBcAg antibody (1:200; Abcam, England) and Alexa
Fluor 488-conjugated goat anti-rabbit IgG (1:200; Jackson
ImmunoResearch, USA). Finally, the sections were stained
with 4′,6-diamidino-2-phenylindole (DAPI) for nuclear
indication. Immunofluorescence analyses were performed
with a fluorescence microscope (Leica, German).pET21b-IFN-CSP. a: SDS-PAGE analyses of IFN-CSP expression at different
pET21b-IFN-CSP before induction; Lanes 2–8: E. coli BL21/pET21b-IFN-CSP
Percentage and concentration of IFN-CSP were calculated by the target
Fig. 6 Effect of different IPTG concentration on the expression level of IFN-CSP in E. coli BL21/pET21b-IFN-CSP. a: SDS-PAGE analyses of IFN-CSP
expression using different IPTG concentration. Lane M: Protein molecular weight marker; Lane 1: E. coli BL21/pET21b-IFN-CSP before induction;
Lanes 2–9: IPTG concentrations are 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2 and 1.5 mmol/L, respectively. b: Percentage and concentration of IFN-CSP were
calculated by the target bands in SDS-PAGE (A)
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western blot procedure using primary polyclonal anti-
HBcAg antibody (1:200; Abcam, England), anti-actin
monoclonal antibody (1:1000; Santa Cruz Biotechnology,
USA) and peroxidase-conjugated secondary antibodies.
The image was digitized using a scanner and signal was
quantified using of Quantity One software (Bio-Rad).
Statistical analysis
Each measurement was performed at least in triplicate.
All data were expressed as the mean ± standard error of
the mean (SEM). All statistical analyses were performed
by SPSS (version 13.0 for Windows) statistical software.
Differences between mean values were analyzed using
One-Way Analysis of Variance (ANOVA). Statistical sig-
nificance was defined by a P value of less than 0.05.
Results
Construction of the liver-targeting fusion interferon gene
using E. coli preferred codon
To create a modified IFN-CSP gene with enhanced
translation efficiency compared to the native gene, we
designed a codon-optimized version of the IFN-CSPFig. 7 Effect of post-induction time on the expression level of IFN-CSP in E
at different post-induction time. Lane M: Protein molecular weight marker;
BL21/pET21b-IFN-CSP after induced 1, 2, 4, 6, 8, 10, 12 and 24 h, respective
target bands in SDS-PAGE (A)gene (GenBank Accession No. KP027473), which the
rare codons of E. coli were changed to the preferential
codons (Fig. 2). The new modified IFN-CSP gene has
the identical amino acid sequence as the native gene. To
increase the translation termination efficiency, the preferred
stop codon TAAT was used. Finally, restriction enzyme sites
for Nde I and Xho I were introduced at the 5′- and 3′-ends of
the IFN-CSP gene to provide convenient restriction sites for
cloning into the bacterial expression vector. Using SOE-PCR
method, the synthetic IFN-CSP gene with the optimized co-
dons was obtained (Fig. 3) and identified by DNA sequencing.
Plasmids construction and protein expression
The above synthetic IFN-CSP gene fragment was cloned into
the bacterial expression vector pET-21b to construct the
expression plasmid IFN-CSP/pET-21b (Fig. 1a). The correct
synthetic sequence in the recombinant plasmid IFN-CSP/
pET-21b was identified by restriction enzymes with Nde I/Xho
I, showing the expected about 600 bp DNA fragment (data
not shown). The plasmid was then transformed into the bac-
terial expression host E.coli BL21 (DE3) to obtain recombinant
strain. The target protein, which about 21.5 kD, was success-
fully expressed (Fig. 1b) in the form of inclusion bodies (IB).. coli BL21/pET21b-IFN-CSP. a: SDS-PAGE analyses of IFN-CSP expression
Lane 1: E. coli BL21/pET21b-IFN-CSP before induction; Lanes 2–9: E. coli
ly. b: Percentage and concentration of IFN-CSP were calculated by the
Fig. 8 Optimization of IFN-CSP expression by orthogonal test
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Several one-factor experiments and an orthogonal test
(L(9)(3)(4)) were employed to optimize the induction
conditions.
Cultivation temperature
It is well-known that temperature has a great impact
on the recombinant protein expression. Effects of
temperature on IFN-CSP expression were investigated at
17, 22, 27, 32, 37 and 42 °C, respectively. The results
(Fig. 4) revealed that IFN-CSP achieved a high percent-
age in total proteins and a high concentration in the
temperature range of 32–37 °C.Fig. 9 Characterization of recombinant protein by SDS-PAGE, western blot,
molecular weight marker, Lane 1–2: Total proteins of E. coli BL21/pET-21b-IFN-C
after ultrasonication and centrifugation. Lane 5: Purified IFN-CSP using trion and
b: IFN-CSP was analyzed by western blot. Lane M: Protein molecular weight m
after induction. c: Analysis of purified IFN-CSP by RP-HPLC with a C18 column.
Voyager MALDI-TOF mass spectrometryInduction timing
IPTG induction initiates the translation of heterologous
protein. The effect of induction timing was evaluated by
adding IPTG at different stages of growth phase. The re-
sults (Fig. 5) revealed that the percentage of target pro-
tein to total proteins varied from 20.12 to 61.62% at
different induction timing. The maximum percentage
was observed when induced at the midexponential
phase, corresponding to the OD600 value of 0.4–0.8.
IPTG concentration
Effects of final IPTG concentration on IFN-CSP expres-
sion were investigated at 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2
and 1.5 mM, respectively. The results (Fig. 6) revealed
that the percentage of target protein in the total proteins
and the concentration of IFN-CSP achieved the highest
level in the IPTG range of 0.4–0.8 mM.
Post-induction time
The results of optimal post-induction time (Fig. 7) revealed
that the percentage of IFN-CSP to total proteins varied
from 32.55 % to 60.89 % at different post-induction time.
The maximum percentage was observed the product
reached the highest concentration after a 6–10 h induction.
Orthogonal test
Based on the results of one-factor experiments, four pa-
rameters were further optimized by an orthogonal test
(L(9)(3)(4)). The result of orthogonal test was showed thatRP-HPLC and MALDI-MS. a: Purification of IFN-CSP. Lane M: Protein
SP before and after induction, Lane 3–4: Supernatant and precipitation
urea wash. Lane 6: Purified IFN-CSP using HiTrap affinity chromatography.
arker. Lane 1–2: Total proteins of E. coli BL21/pET-21b-IFN-CSP before and
d: Mass spectrum of purified IFN-CSP recorded on an Applied Biosytems
Table 2 Isolation of IFN-CSP from E. coli inclusion bodies with a
recovery protocol
Process step Total protein Purity IFN-CSP Recovery yield
(mg/L) (%) (mg/L) (%)
Cell lysis 3512 61.62 2164.09 100.00
Centrifugation 2536 79.09 2005.72 92.68
Triton wash + Urea wash 1894 85.97 1628.27 81.18
Solubilization 1690 86.39 1459.99 89.60
Refolding 1359 87.16 1184.50 81.13
HiTrap affinity 735 99.85 733.89 61.96
Dialysis 691 99.85 690.00 93.73
Total protein concentration was determined by Bradford method. Purity of
IFN-CSP was calculated from densitometry analysis of SDS-PAGE gels. The
concentration of IFN-CSP was calculated according the percentage fraction
and total protein concentration
Fig. 10 Distribution of IFN α2b and IFN-CSP in liver (a), heart (b), spleen (c
IFN-CSP in mice at 30, 60, 120, 240 and 480 min post-injection. Each point
significant differences of p <0.01 and p <0.05, respectively between IFN α2
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was inducing the culture at OD600 = 0.6 with 0.8 mM
IPTG for 6 h at 37 °C. The target protein was up to 2.17 g
per L culture (Fig. 8). Main influence factor was induction
temperature (data not shown).Purification, antigenicity and biological activity analysis
The total improved isolation scheme was showed in Fig. 9.
The results of SDS-PAGE and RP-HPLC revealed that the
target protein was purified to over 95 % homogeneity with
no degradation (Fig. 9a and c). The molecular weight
21,481.76 Da determined by MALDI-MS (Fig. 9d) was
consistent with its calculated value of 21,481.7 Da. Step
yields were calculated and showed in Table 2. The im-
proved isolation scheme were highly efficient in producing
pure IFN-CSP, approximately 690 mg of the pure recom-
binant IFN-CSP was obtained from 1 L of E. coli culture.
The results of western blot analysis revealed that puri-
fied IFN-CSP was strongly and specifically reacted with
the IFN α antibody (Fig. 9b). The results of chromogenic), lung (d), kidney (e) after a single i.v. administration of free IFN α2b or
represents the mean ± SEM (n = 6). The ** and * indicate statistically
b and IFN-CSP treatments
Fig. 11 Effect of IFN α2b, IFN-CSP on serum HBsAg (a) and HBV-DNA (b) level in HBV-transgenic mice. (a) physiological saline control; (b) IFN
α2b, 103 U/g body weight; (c) IFN-CSP, 101 U/g body weight; (d) IFN-CSP, 102 U/g body weight; (e) IFN-CSP, 103 U/g body weight. The treatment
continued for 28 days, serum HBsAg levels were measured by ELISA assay. The results are represented as OD value of sample/OD value of negative
control. Serum HBV-DNA levels were measured by fluorescent quantification polymerase chain reaction (PCR). The copies of the HBV-DNA
were calculated based on their Ct value and the standard curves. The data are the mean ± SEM from six mice. *P < 0.05 vs physiological saline
controls, **P < 0.01 vs physiological saline controls, # #P < 0.01 vs IFN α2b controls
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content in the purified sample was less than 0.5 Eu/mg
proteins. Biological activity analysis using the WISH/
VSV system showed that the above purified sample had
ability to inhibit the cytopathic effect caused by VSV on
WISH cells (3.78 × 108 U/mg).Fig. 12 Effect of IFN α2b, IFN-CSP on HBV core protein in the liver of HBV-tr
saline control; (c) IFN α2b, 103 U/g body weight; (d) IFN-CSP, 101 U/g body w
weight. The treatment continued for 28 days, liver of mice were collected for an
stained with anti-HBcAg antibody are presented. Arrows indicate distinct
with DAPI. Calibration bar =50 μm for photomicrographs. b: The core pro
of the core protein were analyzed using Quantity One software. The data
controls, **P < 0.01 vs physiological saline controls, # #P < 0.01 vs IFN α2bIn vivo tissue distribution
To determine whether IFN-CSP was able to accumulate
in liver for potential treatment of hepatitis B, the tissue
distribution of IFN-CSP were evaluated and compared
to native IFN α2b. The ELISA method for IFN α2b detec-
tion is feasible and accurate (data not shown). The IFN-ansgenic mice. a normal non-transgenic mice control; (b) physiological
eight; (e) IFN-CSP, 102 U/g body weight; (f) IFN-CSP, 103 U/g body
alyses. a: Representative photographs of liver sections immunofluorescent
green fluorescent labeling of HBcAg in liver, blue nuclear stained
tein was also quantified by western blot analysis. c: Optical densities
are the mean ± SEM from six mice. *P < 0.05 vs physiological saline
controls
Fig. 13 Protocol for the recovery of IFN-CSP from E. coli
inclusion bodies
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up to 5.48- to 3.22-fold higher than those of native
IFN α2b (p < 0.01) at 30, and 60 min interval post-
administration (Fig. 10).
IFN-CSP reduces serum HBsAg and HBV-DNA in
HBV-transgenic mice
To evaluate the in vivo anti-HBV activity of the recombin-
ant IFN-CSP, Balb/c-HBV transgenic mice were treated
with different concentrations of IFN-CSP for 28 days. As
shown in Fig. 11, IFN-CSP reduces serum HBsAg and
HBV-DNA in HBV-transgenic mice in a dose-dependent
manner. Compared with the native IFN α2b group, the
administration of IFN-CSP at comparable concentrations
significantly reduced serum HBsAg and HBV-DNA.
IFN-CSP reduces HBV core protein in the liver of
HBV-transgenic mice
Livers from HBV-transgenic mice were detected with
anti-HBcAg antibody by immunofluorescent staining and
western blot analysis. The results (Fig. 12) showed that the
signal of HBV core protein is obviously decreased in the
liver of HBV-transgenic mice treated with IFN-CSP in a
dose-dependent manner. IFN α2b control also suppressed
the expression of HBV core protein, but the degree of sup-
pression less than the same dose of IFN-CSP.
Discussion
The expression of heterologous proteins in E. coli is an
attractive strategy to obtain the active form of protein in a
large scale for therapeutic application. In our previous
work, the strategy proved to be efficient to achieve high-
level expression [15, 17]. While, DNA sequence analysis
of genes encoding either high abundance or low abun-
dance proteins in E. coli has revealed a pattern of fa-
vored codon usage [18]. Lowly expressed genes show
the greatest degree of conformity to the rare codons,
which correspond to the rare tRNAs in the E. coli cell.
So, it is necessary to analyze the DNA sequence of
IFN-CSP before recombination expression using E. coli
expression system.
The IFN-CSP contains 184 amino acids, and 15 amino
acids are encoded by the rare codons of E. coli. Particu-
larly, R12, R13, R22, R23, R33, R120, R125, R144, R149,
and R162 were encoded by the least used codons, AGG
and AGA, which were discovered to dramatically reduce
the maximum level of protein synthesis. Some examples
show that codon optimization can significantly improve
the expression level [5, 19]. Srivastava et al. reported that
a codon optimized IFN α2b gene expressed as IB only
about 40 % of the total protein [20]. Valente et al. using
an artificial IFN α2b gene that was codon optimized for
its rare tandem arginine codons and its gene product
was produced 16.6 mg/L E. coli culture [21]. Anotherinvestigation used E. coli codon optimized artificial gene
produced His-IFN α2b in the form of IB -210 mg/L E.
coli culture [22]. Based on the above knowledge, we ap-
plied a codon optimization strategy to over-express IFN-
CSP fusion protein in E. coli. Moreover, stop codon bias
and context also correlates with the efficiency of transla-
tion [23], so the preferred sequence of translation ter-
mination in E. coli, ‘TAAT’ was used.
The induction conditions will affect the expression level
of target proteins as reported numerous times elsewhere
[16, 24]. For this reason, the induction conditions like
cultivation temperature, induction timing, inducer con-
centrations, and induction time were also examined. In
our previous study, we found that the fusion IFN-CSP
without any optimization expressed as IB only accounting
for 39.2 % of the total insoluble protein [13]. In the
present, the highest expression level was achieved when
the recombinant E. coli at the mid-exponential phase was
effectively induced at 37 °C with 0.8 mM IPTG concentra-
tion for 6 h. Although most of the IFN-CSP protein in the
current work was produced in the form of IB (Fig. 1b), this
Lu et al. BMC Biotechnology  (2015) 15:54 Page 11 of 12is the first report to show that the novel liver-targeting fu-
sion interferon (IFN-CSP) was expressed in such high level,
about 61.62 % relative to total host proteins. Using the im-
proved purification scheme (Fig. 13), the final yield of puri-
fied IFN-CSP was up to 690 mg per L culture, which is
2.56-fold higher than the previous investigation [13]. The
purity and the molecular weight of purified IFN-CSP
were demonstrated by SDS-PAGE, RP-HPLC and
MALDI-MS (Fig. 9). The result of western blot analysis
characterized the antigenicity of IFN-CSP (Fig. 9b). Bio-
logical activity analysis according to China Biologicals Re-
quirements showed that IFN-CSP had ability to inhibit the
cytopathic effect caused by VSV on WISH cells (3.78 × 108
U/mg).
In line with previous in vitro experiments, we have
further evaluated the in vivo tissue distribution and anti-
HBV activities of IFN-CSP. In vivo tissue distribution
assay showed that IFN-CSP was able to accumulate in
mouse liver compared to native IFN α2b (Fig. 10). Small
animal models amenable to infection with human hepa-
totropic viruses are in great need for studying new anti-
HBV drugs. The HBV-Tg mouse lineage was initially
produced on a BALB/c background. The transgene in
these mice consists of 1.3 copies of the HBV ayw
complete genome. The HBV-Tg mice express high level
of HBsAg in their serum and have detectable HBV-DNA
in their serum, which allows HBV-DNA replication, is
an appropriate tool to evaluate anti-HBV drugs [25–28].
In the present study, we found that the recombinant
IFN-CSP and native IFN α2b in vivo were able to reduce
serum HBsAg (Fig. 11a), HBV-DNA (Fig. 11b) and liver
HBV core protein (Fig. 12) in HBV-transgenic mice.
However, IFN-CSP showed a significant improvement in
anti-HBV activity when compared with native IFN α2b
at similar doses. These results indicate that incorpor-
ation of plasmodium region I peptide can specifically
target to liver, to achieve higher local concentrations and
to improve their anti-HBV efficacy in vivo.
Conclusion
In this report, synthetic codon optimized IFN-CSP gene
was overexpressed at high expression level and the puri-
fied protein was confirmed to IFN-CSP based on the re-
sults of antigenicity and biological activity analysis. The
purified IFN-CSP was able to accumulate in mouse liver
compared to native IFN α2b and reduce serum HBsAg,
HBV-DNA and liver HBV core protein in HBV-transgenic
mice. This current work reports for the first time that
codon and expression conditions optimized approach is a
strategy to produce IFN-CSP at large scale, and would also
be very helpful to produce other recombinant protein for
further medical research. The present study further sup-
ported the application of IFN-CSP in liver-targeting anti-
HBV medicines.Abbreviations
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